Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients
| Autor: | Koichiro Akakura, Yuzuru Ikehara, Akira Komiya, Hiroomi Nakatsu, Tomokazu Sazuka, Tomohiko Ichikawa, Yasutaka Yamada, Junryo Rii, Manato Kanesaka, Yusuke Imamura, Shinichi Sakamoto, Maihulan Maimaiti |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Bicalutamide CHAARTED study Urology Metastatic castration naïve prostate cancer Androgen deprivation therapy chemistry.chemical_compound Prostate cancer Lactate dehydrogenase Intensive therapy Internal medicine medicine Initial treatment LATITUDE study business.industry Hazard ratio medicine.disease Diseases of the genitourinary system. Urology chemistry Cohort RC870-923 business Research Article medicine.drug |
| Zdroj: | Prostate International, Vol 9, Iss 4, Pp 208-214 (2021) Prostate International |
| ISSN: | 2287-8882 |
| DOI: | 10.1016/j.prnil.2021.06.001 |
| Popis: | Background: To identify the real high-risk group among Japanese de novo metastatic prostate cancer patients who fit CHAARTED or LATITUDE criteria. Methods: We retrospectively studied patients who fitted CHAARTED (292 patients) and LATITUDE (294 patients) criteria from Japanese multi-institutions. All patients received androgen deprivation therapy with bicalutamide as an initial treatment. Factors related to overall survival (OS) and progression-free survival were statistically analyzed. Results: The median OS was 55.5 months and 60.0 months in patients who met the CHAARTED and the LATITUDE criteria, respectively. In patients who met CHAARTED criteria, lactate dehydrogenase (LDH) (hazard ratio (HR) 2.63, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|